Grants

Welcome to the FTI-Project iLCA: Intelligent Live Cell Analysis [iLCA] to transform disease management through faster, and more regulatory robust, discovery, manufacture and monitoring of biologic drugs and cell therapies.

iLCA Platform

Our objective is to introduce an intelligent Live Cell Analysis platform into Cell Line Development [CLD] which provides end-users with a Manufacturability index containing detailed information on their clones, which is currently only available much later in the decision making process. The overarching objective of iLCA is to, over the next 24 months, rapidly validate the technical and economic performance of our disruptive process analytical platform at leading biopharmaceutical manufacturing sites.